SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

C4X Discovery to receive $13m milestone under AZN NRF2 license

C4X Discovery Holdings says it will receive a $13 million milestone payment from AstraZeneca after an oral NRF2 activator programme enters the clinic under its exclusive worldwide license agreement.

AZN

4 September 2026 — C4X Discovery Holdings Ltd (“C4XD”) said it will receive a $13 million milestone payment from AstraZeneca [LON: AZN] after the oral NRF2 activator programme entered the clinic. The company said the payment is triggered under the terms of the licensing…

Related stories